Hangzhou Tigermed Consulting Co (HKSE:03347) EBIT per Share : HK$0.81 (TTM As of Mar. 2025)

View and export this data going back to 2020. Start your Free Trial

What is Hangzhou Tigermed Consulting Co EBIT per Share?

Hangzhou Tigermed Consulting Co's EBIT per Share for the three months ended in Mar. 2025 was HK$0.23. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2025 was HK$0.81.

During the past 12 months, the average EBIT per Share Growth Rate of Hangzhou Tigermed Consulting Co was -45.60% per year. During the past 3 years, the average EBIT per Share Growth Rate was -7.80% per year. During the past 5 years, the average EBIT per Share Growth Rate was 9.40% per year. During the past 10 years, the average EBIT per Share Growth Rate was 24.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Hangzhou Tigermed Consulting Co's EBIT per Share or its related term are showing as below:

HKSE:03347' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -7.8 Med: 28.1 Max: 96.5
Current: -7.8

During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Hangzhou Tigermed Consulting Co was 96.50% per year. The lowest was -7.80% per year. And the median was 28.10% per year.

HKSE:03347's 3-Year EBIT Growth Rate is ranked worse than
61.9% of 168 companies
in the Medical Diagnostics & Research industry
Industry Median: 4.85 vs HKSE:03347: -7.80

Hangzhou Tigermed Consulting Co's EBIT for the three months ended in Mar. 2025 was HK$201 Mil.

Hangzhou Tigermed Consulting Co EBIT per Share Historical Data

The historical data trend for Hangzhou Tigermed Consulting Co's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hangzhou Tigermed Consulting Co EBIT per Share Chart

Hangzhou Tigermed Consulting Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

EBIT per Share

Get a 7-Day Free Trial

3.37

5.22

3.45

3.30

1.00

Hangzhou Tigermed Consulting Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
EBIT per Share	Get a 7-Day Free Trial															0.44	0.51	0.43	-0.36	0.23

Hangzhou Tigermed Consulting Co EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Hangzhou Tigermed Consulting Co's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	860.22	/	862.007
=	1.00

Hangzhou Tigermed Consulting Co's EBIT per Share for the quarter that ended in Mar. 2025 is calculated as

	EBIT per Share		(Q: Mar. 2025 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	200.914	/	870.888
=	0.23

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$0.81

Hangzhou Tigermed Consulting Co (HKSE:03347) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Hangzhou Tigermed Consulting Co EBIT per Share Related Terms

Thank you for viewing the detailed overview of Hangzhou Tigermed Consulting Co's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Hangzhou Tigermed Consulting Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Hangzhou Tigermed Consulting Co Ltd (HKSE:03347) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

5HZ1:Germany 300347:China

Address

Block 8, No. 19 Jugong Road, Room 2001-2010, 20th Floor, Xixing Sub-District, Binjiang District, Hangzhou, CHN, 310053

Website

https://www.tigermed.net

Hangzhou Tigermed Consulting Co Ltd is a China-based Contract Research Organization. The company's segment includes Clinical trial solutions and Clinical-related and laboratory services. It generates maximum revenue from the Clinical trial solutions segment. The company's offered services include bioanalytical, medical writing, biostatistics analysis, and medical imaging. The therapeutic areas of the company include Infections, Hematology, Cardiovascular, Endocrinology, Rheumatology, Nephrology, and Central Nervous System (CNS) among others.

Executives

Sands Capital Management, Llc	2101 Beneficial owner
Sands Capital Management, Lp	2201 Interest of corporation controlled by you
Sands Family Trust, Llc	2201 Interest of corporation controlled by you
Sands Frank Melville Jr.	2201 Interest of corporation controlled by you
Yi Fang Da Ji Jin Guan Li You Xian Gong Si	2102 Investment manager
Jpmorgan Chase & Co.	2201 Interest of corporation controlled by you
F-j Sands Family I, Llc	2201 Interest of corporation controlled by you
2017 Eagle Holdings Llc	2201 Interest of corporation controlled by you
Citigroup Inc.	2201 Interest of corporation controlled by you
Ubs Group Ag	2201 Interest of corporation controlled by you
Blackrock, Inc.	2201 Interest of corporation controlled by you
Brown Brothers Harriman & Co.	2502 Approved lending agent
Ninety One Plc/ Ninety One Ltd	2102 Investment manager
Ninety One Uk Limited	2102 Investment manager
Baillie Gifford & Co	2102 Investment manager

Hangzhou Tigermed Consulting Co Headlines

No Headlines